Stay updated on Pembrolizumab in HER2+ Gastric Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in HER2+ Gastric Clinical Trial page.

Latest updates to the Pembrolizumab in HER2+ Gastric Clinical Trial page
- Check3 days agoChange DetectedThe webpage has been updated to reflect new results and criteria for a clinical study involving pembrolizumab and trastuzumab for HER2 positive gastric cancer, with specific details on treatment protocols and efficacy measures. The results reporting dates have also been updated.SummaryDifference14%
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page now indicates that results have been submitted, replacing the previous message that no results were posted.SummaryDifference0.1%
- Check25 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.6%
- Check41 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference0.6%
- Check48 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.0%
- Check62 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.0%
Stay in the know with updates to Pembrolizumab in HER2+ Gastric Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HER2+ Gastric Clinical Trial page.